Zhaoke Ophthalmology’s Partner Vyluma Announces FDA Acceptance of New Drug Application for NVK002, its Novel Investigational Treatment for Pediatric Myopia

Zhaoke Ophthalmology’s Partner Visus Therapeutics Announces Positive Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL PF™ for the Treatment of Presbyopia

Zhaoke Ophthalmology Enters Into A Distribution and Supply Agreement With Kwangdong Pharmaceutical To Commercialize NVK002 In South Korea

Zhaoke Ophthalmology Announces 2022 Annual Results

Zhaoke Ophthalmology Commences Commercialisation of its First Drug with Bimatoprost Timolol Eye Drop (晶贝莹®) Obtaining Marketing Authorization from the National Medical Products Administration